Ozempic
semaglutide · GLP-1 receptor agonist
Ozempic is semaglutide from Novo Nordisk, available as a once-weekly injection and, since May 2026, as a once-daily pill that replaced the Rybelsus brand in the US. It is FDA-approved for blood sugar control in type 2 diabetes, for reducing cardiovascular events in people with established heart disease, and for slowing kidney disease progression. Injection doses step up from 0.25 mg to 2 mg. Common side effects are gastrointestinal, and a boxed warning covers thyroid C-cell tumor risk. List price is about $1,027/mo, with self-pay routes from $199/mo.
GLP-1 RA
Weekly or daily
5–8%
$1,027/mo
Overview
Ozempic is the brand name for semaglutide from Novo Nordisk, in the GLP-1 receptor agonist class. It mimics a natural gut hormone that regulates blood sugar and appetite. It is FDA-approved to improve glycemic control in adults with type 2 diabetes, to lower cardiovascular risk in those with known heart disease, and to slow kidney disease progression in people with type 2 diabetes and chronic kidney disease. It is available as a once-weekly injection and, since May 2026, as a once-daily tablet that replaced the Rybelsus brand in the US. Ozempic is not FDA-approved for weight loss; its sister product Wegovy is, though many people lose weight on it.
How Ozempic works
Curbs appetite
Slows digestion
Steadies blood sugar
What it's used for
- Improve blood sugar (A1C) in adults with type 2 diabetes
- Reduce major cardiovascular events in type 2 diabetes with established heart disease
- Slow kidney disease progression and reduce cardiovascular death in type 2 diabetes with chronic kidney disease
- Off-label weight management under clinician guidance
Effectiveness
In the SUSTAIN trials, Ozempic lowered A1C by roughly 1.5 to 1.8 points and produced about 5% to 8% mean body-weight loss, more at the 2 mg dose. In SUSTAIN-6, it reduced major adverse cardiovascular events in people with type 2 diabetes at high cardiovascular risk. In FLOW, it slowed kidney function decline in people with type 2 diabetes and chronic kidney disease, which is the basis for the renal indication. Higher-dose semaglutide sold as Wegovy reached about 15% body-weight loss in STEP 1. Individual results vary.
Dosing schedule
Injection (once weekly)
Pill (once daily)
Ozempic tablets are taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before any other food, drink, or oral medication. The tablet carries the type 2 diabetes and cardiovascular indications; the kidney indication applies to the injection.
Side effects & Safety
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
Serious risks & warnings
- Thyroid C-cell tumor risk (boxed warning)
- Pancreatitis
- Gallbladder problems
- Low blood sugar with insulin/sulfonylureas
- Kidney injury from dehydration
- Diabetic retinopathy changes
- Severe gastrointestinal reactions
- Pulmonary aspiration during general anesthesia or deep sedation
Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Cost & savings
List price is about $1,027/mo without insurance. Most people pay less through one of these routes:
Through insurance
As low as $25
Telehealth cash-pay
$99/mo
Patient assistance
$0
Self-pay through NovoCare Pharmacy is $349/mo for the 0.25, 0.5, and 1 mg pens and $499/mo for the 2 mg pen, with a $199 introductory rate on the first two fills of the two lowest doses. The Ozempic pill starts at about $149/mo for the lowest dose. Savings card and self-pay offers exclude Medicare, Medicaid, TRICARE, and VA beneficiaries. Prices verified August 2026.
Compare with other GLP-1s
Frequently asked questions
Is Ozempic approved for weight loss?
No. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease. Wegovy is the semaglutide product approved for chronic weight management. Many people do lose weight on Ozempic, but that use is off-label.
What is the difference between the Ozempic pen and the Ozempic pill?
Both contain semaglutide. The pen is a once-weekly subcutaneous injection at 0.25 to 2 mg. The pill is a once-daily tablet at 1.5, 4, or 9 mg, launched in the US in May 2026 to replace the Rybelsus brand. The pen carries the kidney indication; the pill does not.
How much weight do people lose on Ozempic?
In the SUSTAIN trials, mean weight loss was roughly 5% to 8% of body weight, with more at the 2 mg dose. Higher-dose semaglutide sold as Wegovy reached about 15% in STEP 1. Individual results vary.
How long does it take Ozempic to work?
Blood sugar improvements often appear within the first few weeks. Full effect builds over about 8 to 12 weeks as the dose steps up from the starter dose to a maintenance dose.
What does Ozempic cost without insurance?
List price is roughly $1,027 per month. Self-pay through NovoCare Pharmacy is $349 per month for 0.25 to 1 mg and $499 per month for 2 mg, with a $199 introductory rate on the first two fills of the two lowest doses. Income-qualified uninsured patients may receive it at no cost through patient assistance.
Educational only, not medical advice. Ozempic is a prescription medication; a licensed clinician determines if it's appropriate. Effectiveness figures are trial averages (SUSTAIN, SUSTAIN-6, FLOW); results vary. Ozempic is not FDA-approved for weight loss. Pricing verified August 2026 and subject to change. *Starting price for doctor-guided care; medication cost is separate.